Paydirt
RN
Insider

Robert Nelsen

Director

Robert Nelsen (Director) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in PRME. Across 1 priced purchase filing, the average 21-session return was -7.7% from execution and -7.7% from disclosure (delay-adjusted; derived). The largest single filing was $10.0M of PRME (3,030,300 sh × $3.30, as filed), executed Aug 1 2025.

Add to watchlist
Return, ttmiAverage return per filing, trailing twelve months
-7.7%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-7.7%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
0d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$10.0M
shares × price, as filed
Last traded
Aug 1 2025
Filed Aug 1 2025
Open performance
Volume by month
$10.0M$5.0M$0Oct 2024Apr 2025Oct 2025Apr 2026Aug 2025 · buys $10.0M
Buys $10.0M Sells $0

Shares × price, as filed · by filing month · past 24 months

Sectors filed on
Not on file 1 filing

Sector per market data · by filing · past 24 months

Most traded names
PRME PRME PRME · 1 buy · 0 sells 1 filing
Recent filings
PRMEPURCHASE Prime Medicine, Inc. View filing → $10.0M
3,030,300 sh × $3.30
Exec Aug 1 2025
Filed Aug 1 2025 · 7:19 PM ET